Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).

Early abiraterone acetate treatment improves outcomes in CRPC patients

28 Feb 2018

In chemotherapy-naïve castrate-resistant prostate cancer (CRPC) patients, first- and second-line administration of abiraterone acetate (AA) treatment leads to favourable outcomes, a recent Japan study suggests.

Researchers retrospectively analysed the records of 69 CRPC patients who received AA treatment and classified them into two: the early group, who received AA as first- or second-line treatment (n=24), and the deferred group, who received AA as a third-line or later treatment (n=45).

In unadjusted analyses, only the timing of AA treatment was significantly associated with progression-free survival (PFS), such that those in the early group had better outcomes than those in the deferred group (hazard ratio [HR], 3.29; 95 percent CI, 1.66–6.51; p<0.001).

Adjusting for potential confounders did not attenuate the relationship. Although to a slightly lesser degree, early AA treatment remained significantly correlated with better PFS outcomes (HR, 2.99; 1.35–6.64; p<0.01).

Within the early group, there were no significant differences in outcomes between those who received AA as first- or second-line treatment. That is, patients treated first- or second-line treatment were statistically comparable in terms of prostate-specific antigen response, overall survival and PFS. All participants who received AA as second-line treatment were given flutamide as first-line therapy.

Five patients reported grade 3 adverse events, three of whom had hepatic function. Hypokalaemia and thrombocytopaenia were reported in one patient each. Other adverse events reported were either grade 1 or 2, the most common of which was an increase in alanine aminotransferase or aspartate aminotransferase levels.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).